» Articles » PMID: 1371712

Combined Assessment of Vascular and Myometrial Invasion As a Model to Predict Prognosis in Stage I Endometrioid Adenocarcinoma of the Uterine Corpus

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 1992 Mar 15
PMID 1371712
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The prognostic significance of vascular invasion as compared with other pathologic features was evaluated in 102 cases of endometrioid adenocarcinoma confined to the uterus (Stage I) treated by hysterectomy. By univariate analysis, survival most closely correlated with patient age, architectural grade, depth of myometrial invasion, vascular invasion, and the presence of perivascular lymphocytic infiltrates. Among these, vascular invasion and the presence of perivascular lymphocytic infiltrates were the best indicators of prognosis. In contrast to perivascular lymphocytic infiltrates, the presence of a lymphocytic infiltrate at the tumor-myometrial junction was not related to outcome. The presence of vascular invasion was found to be associated closely with perivascular lymphocytic infiltrates. These two features may be related biologically and were designated "vascular invasion-associated changes." By multivariate analysis with the Cox proportional hazards model, the depth of myometrial invasion and the presence of vascular invasion-associated changes were found to provide a highly reliable model for predicting outcome. The highly predictive value of vascular invasion as a prognostic factor in Stage I endometrial carcinoma suggests that it is the mechanism by which occult metastasis develops in patients whose disease progresses after hysterectomy. It is likely that other variables correlating with recurrence, such as the presence of deep myometrial invasion and high tumor grade, may act by increasing the probability of vascular invasion and subsequent metastasis.

Citing Articles

Practical guidance for assessing and reporting lymphovascular space invasion (LVSI) in endometrial carcinoma.

Peters E, Nucci M, Gilks C, McCluggage W, Bosse T Histopathology. 2024; 86(2):173-182.

PMID: 38937066 PMC: 11649510. DOI: 10.1111/his.15272.


The Evolving Landscape of Immunotherapy in Uterine Cancer: A Comprehensive Review.

Haj Hamoud B, Sima R, Vacaroiu I, Georgescu M, Bobirca A, Gaube A Life (Basel). 2023; 13(7).

PMID: 37511876 PMC: 10381911. DOI: 10.3390/life13071502.


Intraepithelial lymphocytes are indicators of better prognosis in surgically resected endometrioid-type endometrial carcinomas at early and advanced stages.

Kono-Sato T, Miyai K, Yamagishi Y, Miyamoto M, Takano M, Matsukuma S BMC Cancer. 2022; 22(1):361.

PMID: 35366828 PMC: 8977032. DOI: 10.1186/s12885-022-09363-0.


Natural Kinase Inhibitors for the Treatment and Management of Endometrial/Uterine Cancer: Preclinical to Clinical Studies.

Singla R, Behzad S, Khan J, Tsagkaris C, Gautam R, Goyal R Front Pharmacol. 2022; 13:801733.

PMID: 35264951 PMC: 8899191. DOI: 10.3389/fphar.2022.801733.


Association of Myometrial Invasion With Lymphovascular Space Invasion, Lymph Node Metastasis, Recurrence, and Overall Survival in Endometrial Cancer: A Meta-Analysis of 79 Studies With 68,870 Patients.

Wang J, Xu P, Yang X, Yu Q, Xu X, Zou G Front Oncol. 2021; 11:762329.

PMID: 34746002 PMC: 8567142. DOI: 10.3389/fonc.2021.762329.